A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00685841 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

717

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: Arformoterol tartrate inhalation solution
DRUG: Arformoterol tartrate inhalation solution
DRUG: Arformoterol tartrate inhalation solution
DRUG: Salmeterol MDI
DRUG: Placebo

Sponsor

Sumitomo Pharma America, Inc.